UNICREDIT BANK/CALL/AMGEN/350/0.1/18.12.24 | Real-time BOERSE MUENCHEN 11:40:12 2024-07-04 am EDT | ||
| 1.01 EUR | +1.00% |
|
| Current month | -11.50% | ||
| 3 months | +104.08% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-07-04 | 1.01 | +1.00% |
| 24-07-03 | 1 | -9.09% |
| 24-07-02 | 1.1 | 0.00% |
| 24-07-01 | 1.1 | -2.65% |
| 24-06-28 | 1.13 | -0.88% |
Real-time BOERSE MUENCHEN
Last update July 04, 2024 at 11:40 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HC3JAL |
| ISIN | DE000HC3JAL0 |
| Date issued | 2023-01-26 |
| Strike | 350 $ |
| Maturity | 2024-12-18 (167 Days) |
| Parity | 10 : 1 |
| Emission price | 0.99 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.25 € |
|---|---|
| Lowest since issue | 0.13 € |
| Spread | 0.12 € |
| Spread % | 11.01% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
309.4
USD
Average target price
316.4
USD
Spread / Average Target
+2.28%
- Stock Market
- Warrants
- Warrant
